ArticleFrontiers in endocrinology2026
Comparative discriminative ability of CVAI and traditional insulin resistance indices for MAFLD in Chinese adults with type 2 diabetes.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metabolic dysfunction-associated fatty liver disease (MAFLD) is highly prevalent in patients with type 2 diabetes mellitus (T2DM), necessitating simple and reliable non-invasive screening tools. The Chinese Visceral Adiposity Index (CVAI) has been developed to assess visceral adipose dysfunction, but its discriminative performance for MAFLD compared with traditional insulin resistance (IR) indices in T2DM populations remains unclear. Methods: This retrospective cross-sectional study included 2,945 Chinese adults with T2DM recruited from 45 community health centers. We calculated seven IR indices: CVAI, TyG, TyG-BMI, TyG-WC, TyG-WHtR, METS-IR, and SPISE. Multivariable logistic regression was employed to assess independent associations with MAFLD. Discriminative ability was evaluated using receiver operating characteristic (ROC) curve analysis with Delong's tests. Net reclassification improvement (NRI) and integrated discrimination improvement (IDI) were calculated to assess incremental discriminative value over a baseline clinical model. Restricted cubic spline (RCS) regression, decision curve analysis (DCA), and subgroup analyses were also performed. Results: Among participants, 1,313 (44.6%) were diagnosed with MAFLD. All IR indices were independently associated with MAFLD after full adjustment (all P < 0.001). CVAI demonstrated the highest discriminative ability (AUC = 0.754, 95% CI: 0.737-0.771), significantly outperforming all other indices (all P < 0.001). Adding CVAI to the baseline model significantly improved risk reclassification (NRI = 0.598, 95% CI: 0.533-0.665; IDI = 0.081, 95% CI: 0.072-0.090) and yielded the broadest clinical utility across threshold probabilities of 10-90% in DCA. The association between CVAI and MAFLD was significantly stronger in females and older adults (both P for interaction < 0.05). RCS analysis revealed a predominantly linear relationship (non-linear P = 0.0581). Conclusion: CVAI is independently associated with MAFLD and exhibits superior discriminative performance compared with traditional IR indices in Chinese adults with T2DM. As a simple, non-invasive index derived from routine clinical parameters, CVAI holds promise as an effective screening tool for MAFLD, particularly in females and older adults. Prospective studies are warranted to validate its diagnostic utility.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.